To evaluate the efficacy and safety in adolescent boys with idiopathic short stature (ISS) when treated with third-generation aromatase inhibitors (AIs), the combination of letrozole or anastrozole with recombinant human GH (rhGH), and compare adult height (AHt) augmentation following the treatment with rhGH combined with AIs or GnRH analog (GnRHa) in male adolescents with ISS. Here, CYP19A1 is linked to SHOX-related short stature.